Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by JohnnyYegon Aug 28, 2023 12:31am
239 Views
Post# 35607636

RE:RE:RE:RE:RE:RE:Cmon Mat!(not Brad).....let’s see a nice positive update!

RE:RE:RE:RE:RE:RE:Cmon Mat!(not Brad).....let’s see a nice positive update!Folks, I guarantee you that management and the BOD know exactly what is going on in the industry regarding past, current and future possible compounds that may or may not become SOC. Conversely no one on this or any board knows what other products are pending as possible "direct" competition for the exact indications Pela is targeted at. 

I understand in the absence of news and with little communication from the company - most likely due to ongoung negotiations around PANCAN, with the FDA, and possibly BD deals - its easy to fabricate scenarios. But until something concrete is delivered by way of a NR, EVERYTHING on here is pure speculation.

I await the repercussions of this post... ;) 
<< Previous
Bullboard Posts
Next >>